Institut National de la Santé et de la Recherche Médicale (INSERM), U851, Lyon, France.
PLoS One. 2007 Mar 28;2(3):e330. doi: 10.1371/journal.pone.0000330.
Hepatitis C virus (HCV) can be purified from serum of chronically-infected patients in the form of Lipo-Viro-Particles (LVP), which are triglycerid-rich lipoprotein-like particles containing viral RNA and proteins. Since LVP is a constant feature of chronically infected patients, we asked whether purified LVP could interfere with the immune response by acting directly on dendritic cell (DC) function.
We have analyzed the impact of LVP on the maturation monocyte-derived DC induced by TLR3 or TLR4 ligands. Following incubation with LVP, immature DC supported weak transient HCV-RNA replication and type I IFN synthesis. This, however, did not lead to viral particle production nor to maturation of DC. LVP-treatment prior to TLR3 stimulation by polyI:C only enhanced the secretion of IL-12, IL-6 and TNFalpha yielding typical mature DC. In contrast, LVP-treated DC activated by the TLR4 ligand LPS yielded phenotypically mature DC with reduced capacity to secrete both pro- and anti-inflammatory cytokines. Their ability to stimulate allogeneic T lymphocytes was strongly affected since activated T cells produced IL-5 and IL-13 instead of IFNgamma. Addition of IFNalpha prevented the effect of LVP on DC function. Restoration of IFNgamma secretion by T cells was obtained by blocking ERK activation in DC, while induction of IL-5 and IL-13 secretion was inhibited by blocking the p38-MAPK pathway in DC.
LVP can interfere with TLR4-triggered maturation of DC, inducing a shift in DC function that stimulates Th2 cells instead of Th1, by a mechanism that is ERK- and p38-MAPK-dependent. The effect of LVP on DC polarization was reversed by IFNalpha, providing an additional rationale for the interferon therapy of chronically-infected patients. By acting on TLR4 pathway with LVP, HCV may thus exploit a natural protective mechanism of the liver and the intestine normally used to control inflammation and immunity to commensal microorganisms.
丙型肝炎病毒(HCV)可以以富含甘油三酯的脂蛋白样 Lipo-Viro-Particles(LVP)的形式从慢性感染患者的血清中纯化出来,这些 LVP 含有病毒 RNA 和蛋白质。由于 LVP 是慢性感染患者的一个恒定特征,我们想知道纯化的 LVP 是否可以通过直接作用于树突状细胞(DC)功能来干扰免疫反应。
我们分析了 LVP 对 TLR3 或 TLR4 配体诱导的成熟单核细胞来源的 DC 的影响。孵育 LVP 后,不成熟的 DC 支持短暂的 HCV-RNA 复制和 I 型 IFN 合成。然而,这并没有导致病毒颗粒的产生,也没有导致 DC 的成熟。LVP 处理在前 TLR3 刺激多聚 I:C 只增强了 IL-12、IL-6 和 TNFalpha 的分泌,产生典型的成熟 DC。相比之下,用 TLR4 配体 LPS 处理的 DC 被激活后,表型成熟的 DC 分泌促炎和抗炎细胞因子的能力降低。它们刺激同种异体 T 淋巴细胞的能力受到强烈影响,因为激活的 T 细胞产生了 IL-5 和 IL-13,而不是 IFNgamma。IFNalpha 的添加可防止 LVP 对 DC 功能的影响。通过在 DC 中阻断 ERK 激活来恢复 T 细胞的 IFNgamma 分泌,而通过在 DC 中阻断 p38-MAPK 途径来抑制 IL-5 和 IL-13 的分泌。
LVP 可以干扰 TLR4 触发的 DC 成熟,通过一种依赖于 ERK 和 p38-MAPK 的机制,诱导 DC 功能向刺激 Th2 细胞而不是 Th1 细胞的转变。IFNalpha 逆转了 LVP 对 DC 极化的影响,为慢性感染患者的干扰素治疗提供了额外的依据。通过在 TLR4 途径上作用于 LVP,HCV 可能利用肝脏和肠道的自然保护机制,这些机制通常用于控制炎症和对共生微生物的免疫。